REDUCING BLOOD DONOR EXPOSURE IN VLBW INFANTS

减少 VLBW 婴儿的献血者暴露

• 批准号: 6122610
• 负责人: RICHARD A. EHRENKRANZ
• 金额: $ 2.58万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122610
• 关键词: blood donor; blood transfusion; clinical research; erythropoietin; human subject; human therapy evaluation; infant human (0-1 year); low birth weight infant human

Preterm infants with birthweight less than 1250g will be studied to determine if treatment with recombinant human erythropoietin (EPO) beginning in the first 4 days of life and continuing through discharge or 35 weeks post conceptional age can: reduce the number of transfusion- related donor exposures and the number of transfusions; increase the number of non-transfused infants that occur when dedicated units of red blood cells and transfusion guidelines are used in comparison to infants who are not treated with EPO. (This is a NICHD Neonatal Research Network Trial.)

将研究出生体重小于1250 g的早产儿，以确定从出生后4天开始并持续至出院或受孕后35周的重组人促红细胞生成素（EPO）治疗是否可以：与未接受EPO治疗的婴儿相比，使用专用红细胞单位和输血指南时未输血婴儿的数量增加。 (This是NICHD新生儿研究网络试验。